Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-03-10 Board/Management Inform…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Rättelse: Cantargia förstärker ledningsgruppen inför kliniska studier i sen utvecklingsfas
Board/Management Information Classification · 98% confidence The document is a press release (Pressmeddelande) dated March 10, 2022, announcing a correction ('Rättelse') regarding a change in senior management: Dr. Roger Belusa is appointed interim Chief Medical Officer (CMO), and the former CMO takes a new role. This directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3100 chars), but its primary content is the announcement itself, not a notice about the publication of a separate report, making MANG the most appropriate classification over RPA or RNS.
2022-03-10 Swedish
Correction: Cantargia strengthens executive management in preparation for late-stage clinical development
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in senior personnel: the appointment of Dr. Roger Belusa as interim Chief Medical Officer (CMO) and the reassignment of his predecessor. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in senior management. The document is short and clearly an announcement, not a comprehensive report like a 10-K or IR. Therefore, the appropriate code is MANG.
2022-03-10 English
Cantargia rapporterar positiva prekliniska effektdata för CAN10 som visar anti-fibrotisk och anti-inflammatorisk effekt i systemisk skleros
Regulatory Filings Classification · 95% confidence The document is a press release (Pressmeddelande) from Cantargia AB dated March 1, 2022. It announces positive preclinical efficacy data for their drug candidate CAN10 related to systemic sclerosis. It details scientific findings, quotes the CEO and a collaborating professor, and explicitly states that the results will be presented as a poster at an upcoming conference (7th Systemic Sclerosis World Congress) on March 10-12, 2022. The text concludes with a standard disclaimer about EU Market Abuse Regulation and information about the company. This structure—announcing new scientific/development progress and mentioning an upcoming presentation/publication—is characteristic of an Earnings Release (ER) if it contained financial results, or more generally, a Regulatory Filing (RNS) if it's a general corporate update not fitting other specific categories. Since it is a scientific/development update rather than a formal financial report (like 10-K or IR) or a specific announcement like a dividend or management change, and it is a formal press release mandated for public disclosure, it fits best under the general Regulatory Filings category (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the announcement *about* the data presentation. Given the options, RNS is the most appropriate catch-all for significant, non-financial, mandatory corporate news releases that aren't explicitly defined elsewhere. It is not an Earnings Release (ER) as it focuses purely on preclinical data, not period financial results.
2022-03-01 Swedish
Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press release" and announces new preclinical data regarding the drug CAN10 for systemic sclerosis. It details scientific findings, quotes the CEO, and mentions that the data will be presented at an upcoming congress. This format—a brief announcement of recent developments, often scientific or operational, released to the public and media—is characteristic of a general corporate announcement. It is not a formal regulatory filing like a 10-K, an Earnings Release (ER) which focuses on financial results, or a comprehensive Interim Report (IR). Since it is a general announcement of corporate news that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it serves as a broad communication channel for material, non-financial news.
2022-03-01 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 95% confidence The document is a 'Bokslutskommuniké' (Year-end report) for the period January-December 2021. It contains comprehensive financial data, including income statements, balance sheet items, earnings per share, and detailed management commentary on business performance, clinical trial progress, and future outlook. As it covers a full fiscal year and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report (IR) in the context of European financial reporting standards where year-end reports are often treated as the final quarterly/interim release before the full annual report is published. FY 2021
2022-02-24 Swedish
Annual Report 2021
Annual Report Classification · 100% confidence The document is titled 'FULL YEAR REPORT' for the period 'January - December 2021'. It contains comprehensive financial data, including net sales, operating loss, loss after tax, loss per share, and balance sheet items like cash and cash equivalents. It also includes a 'Chief Executive's Review', detailed project updates, and a business strategy section. Since it covers a full fiscal year and provides substantive financial statements and analysis, it is classified as an Annual Report (10-K). FY 2021
2022-02-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.